Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative.

Abstract:

:This article reports on the 'Assessing Cost-Effectiveness' (ACE) initiative in priority setting from Australia. It commences with why priority setting is topical and notes that a wide variety of approaches are available. In assessing these various approaches, it is argued that a useful first step is to consider what constitutes an 'ideal' approach to priority setting. A checklist to guide priority setting is presented based on guidance from economic theory, ethics and social justice, lessons from empirical experience and the needs of decision-makers. The checklist is seen as an important contribution because it is the first time that criteria from such a broad range of considerations have been brought together to develop a framework for priority setting that endeavors to be both realistic and theoretically sound. The checklist will then be applied to a selection of existing approaches in order to illustrate their deficiencies and to provide the platform for explaining the unique features of the ACE approach. A case study (ACE-Cancer) will then be presented and assessed against the checklist, including reaction from stakeholders in the cancer field. The article concludes with an overview of the full body of ACE research completed to date, together with some reflections on the ACE experience.

authors

Carter R,Vos T,Moodie M,Haby M,Magnus A,Mihalopoulos C

doi

10.1586/14737167.8.6.593

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

593-617

issue

6

eissn

1473-7167

issn

1744-8379

journal_volume

8

pub_type

杂志文章
  • Applying a developmental approach to quality of life assessment in children and adolescents with psychological disorders: challenges and guidelines.

    abstract::Research on the quality of life (QL) of children/adolescents with psychological disorders has flourished over the last few decades. Given the developmental challenges of QL measurements in pediatric populations, the aim of this study was to ascertain the extent to which a developmental approach to QL assessment has be...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.972377

    authors: Carona C,Silva N,Moreira H

    更新日期:2015-02-01 00:00:00

  • Antibiotics and reduced risk of COPD re-exacerbations.

    abstract::Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.33

    authors: Antoniu SA

    更新日期:2009-08-01 00:00:00

  • Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma.

    abstract:OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.978292

    authors: Cangelosi MJ,Ortendahl JD,Meckley LM,Bentley TG,Anene AM,Shriner KM,Fox J

    更新日期:2015-04-01 00:00:00

  • Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.

    abstract::Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.2.111

    authors: Gladman DD,Brown RE

    更新日期:2008-04-01 00:00:00

  • Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain.

    abstract:AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.48

    authors: Wild D,Murray M,Donatti C

    更新日期:2009-10-01 00:00:00

  • National trends in out-of-pocket prescription drug spending among elderly medicare beneficiaries.

    abstract::This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.3.297

    authors: Sambamoorthi U,Akincigil A,Wei W,Crystal S

    更新日期:2005-06-01 00:00:00

  • The German method for setting ceiling prices for drugs: in some cases less data are required.

    abstract::The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.11.45

    authors: Gandjour A,Gafni A

    更新日期:2011-08-01 00:00:00

  • Black or white cat? Ideology meets reality in healthcare finance and provision.

    abstract::Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.6.647

    authors: Lim MK

    更新日期:2006-12-01 00:00:00

  • The START study: when to start to treat with inhaled steroids in asthma?

    abstract::Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.3.3.223

    authors: Antoniu SA

    更新日期:2003-06-01 00:00:00

  • Methods and issues associated with the use of quality-adjusted life-years.

    abstract::In this article, we will focus on how preferences and utilities are measured, including the strengths and limitations of various approaches, discuss their use in estimating quality-adjusted life-years (QALYs) and make some recommendations for further research. Preferences are either measured using direct (visual analo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.100

    authors: Revicki DA,Lenderking WR

    更新日期:2012-02-01 00:00:00

  • Patient satisfaction instruments for cancer clinical research or practice.

    abstract::Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.7

    authors: Brédart A,Sultan S,Regnault A

    更新日期:2010-04-01 00:00:00

  • A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease.

    abstract::Smoking cessation is the only strategy that has shown a lasting reduction in the decline of lung function in patients with chronic obstructive pulmonary disease. This study aims to evaluate the cost-effectiveness of smoking cessation interventions in patients with chronic obstructive pulmonary disease, to assess the q...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.1001976

    authors: Kirsch F

    更新日期:2015-04-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.

    abstract::In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.859525

    authors: Diaby V,Goeree R

    更新日期:2014-02-01 00:00:00

  • Radiotherapy cost-calculation and its impact on capacity planning.

    abstract::The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are dis...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.497

    authors: Lievens Y,Slotman BJ

    更新日期:2003-08-01 00:00:00

  • Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban.

    abstract::This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.1.49

    authors: Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

    更新日期:2007-02-01 00:00:00

  • The Cancer Outcomes Measurement Working Group: rationale overview and a look to the future.

    abstract::In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.4.407

    authors: Snyder C,Gotay CC,Lipscomb J

    更新日期:2006-08-01 00:00:00

  • Interpretation of differential item functioning analyses using external review.

    abstract::Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.22

    authors: Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

    更新日期:2010-06-01 00:00:00

  • Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.

    abstract:INTRODUCTION:In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1277144

    authors: Kwon SH,Park SK,Byun JH,Lee EK

    更新日期:2017-08-01 00:00:00

  • Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa.

    abstract::The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1256775

    authors: Massele A,Burger J,Kalemeera F,Jande M,Didimalang T,Kalungia AC,Matshotyana K,Law M,Malone B,Ogunleye O,Oluka M,Paramadhas BD,Rwegerera G,Zinyowera S,Godman B

    更新日期:2017-04-01 00:00:00

  • Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.

    abstract:OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.1065734

    authors: Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

    更新日期:2015-01-01 00:00:00

  • Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.

    abstract:OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1782748

    authors: Alzaid A,Ladrón de Guevara P,Beillat M,Lehner Martin V,Atanasov P

    更新日期:2020-07-20 00:00:00

  • The challenges of implementing pharmacogenomic testing in the clinic.

    abstract:INTRODUCTION:Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be a...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2017.1385395

    authors: Moyer AM,Caraballo PJ

    更新日期:2017-12-01 00:00:00

  • Threshold denial rates in prior authorization prescription programs.

    abstract::In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.2.165

    authors: Grant WC,Yoder DM,Mullins CD

    更新日期:2004-04-01 00:00:00

  • The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

    abstract:BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1282316

    authors: Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

    更新日期:2017-08-01 00:00:00

  • Quality of care for Medicare beneficiaries with disabilities under the age of 65 years.

    abstract::Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.3.261

    authors: Iezzoni LI

    更新日期:2006-06-01 00:00:00

  • Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

    abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1476142

    authors: Grewal S,Ramsey S,Balu S,Carlson JJ

    更新日期:2018-08-01 00:00:00

  • Economic considerations and future directions for lung volume reduction surgery.

    abstract::Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.6.729

    authors: Reed A,Williams T,Snell G

    更新日期:2003-12-01 00:00:00

  • Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept.

    abstract:AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,meta分析

    doi:10.1586/14737167.2016.1165609

    authors: Regnier SA,Alsop J,Wright J,Nixon R,Staines H,Fajnkuchen F

    更新日期:2016-12-01 00:00:00

  • Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.

    abstract:OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1411193

    authors: Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

    更新日期:2018-06-01 00:00:00